NEWS DETAIL

  • Source : Press Release
  • Date : 2021-02-19
  • Companies : Roche

Organizational and Personnel Changes

TOKYO, February 4, 2021 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced the following organizational changes, effective April 1, 2021, and personnel changes, effective March 23 and April 1, 2021, respectively.

[Details of Organizational Changes]
Effective April 1, 2021
1. Reorganization of Quality & Regulatory Compliance Unit

To strengthen the healthcare compliance management function, the current dual Promotion/Fair-Competition Code management systems in two organizations (Quality & Regulatory Compliance Unit/Marketing & Sales Div.) will be integrated and streamlined into Healthcare Compliance Dept., which will be newly established in Quality & Regulatory Compliance Unit. Regulatory Intelligence & Management Dept. will focus on regulatory management to meet additional operational needs and regulatory requirements for new modalities, and also to take immediate actions for the risk management.

2. Additional function of Medical Affairs Div.

Aiming to realize the personalized healthcare (PHC) through creation of unique evidences, Medical PHC Initiative Dept. will be newly established in Medical Affairs Div. to strengthen planning and promotion of post-marketing PHC strategies. The centralization aims to structure a system which provides PHC related information from various post-marketing clinical environments for the medical front, and to enable more sophisticated delivery of information.

3. Reorganization across Research Div. and Translational Research (TR) Div.

To strengthen and accelerate the seamless transition of in-house R&D projects from the non-clinical stage to the acquisition of clinical proof of concept* (PoC), Research Div. and TR Div. will be partially reorganized. In Research Div., Protein Science Dept. will be newly established while Discovery ADMET** Dept. will be abolished. In TR Div., Pharmaceutical Science Dept. and Non-clinical Safety Assessment Dept. will be newly established while Development ADMET Dept. and Clinical Pharmacology Dept. will be abolished.

* Proof of Concept: Demonstration that the therapeutic effects conceived in the research stage is effective in clinical setting
** ADMET: Absorption, Distribution, Metabolism, Excretion, and Toxicity

[Details of Personnel Changes]
Effective March 23, 2021

Directors

NameNew ResponsibilitiesCurrent Responsibilities
Tatsuro Kosaka Representative Director, Chairman
Supervisory responsibility for Business Development and External Affairs
Representative Director, Chairman
Chief Executive Officer (CEO)
Supervisory responsibility for Corporate Planning, Business Development, External Affairs and Foundation Medicine
Osamu Okuda Representative Director, President
Chief Executive Officer (CEO)
Supervisory responsibility for Clinical Development, Pharmaceutical Technology, Drug Safety, Medical Affairs, Marketing & Sales and Foundation Medicine
Representative Director, President
Chief Operating Officer (COO)
Supervisory responsibility for Project & Lifecycle Management, Regulatory & Quality Management, Clinical Development, Pharmaceutical Technology, Drug Safety, Medical Affairs, and Marketing & Sales

Audit & Supervisory Board Member

NameNew ResponsibilitiesCurrent Responsibilities
Yoshiaki Ohashi Audit & Supervisory Board Member (Full-time) Senior Vice President
Special Mission for CEO
  • The appointment of Yoshiaki Ohashi as Audit & Supervisory Board Member (Full-time) is subject to approval at the 110th Annual General Meeting of Shareholders, which is scheduled to be convened on March 23, 2021.
  • Mamoru Togashi is scheduled to retire from Audit & Supervisory Board Member as of March 23, 2021.

Executive Officers

NameNew ResponsibilitiesCurrent Responsibilities
Hisafumi Okabe Executive Vice President
Supervisory responsibility for Project & Lifecycle Management (R&D), Research and Translational Research
Executive Vice President
Supervisory responsibility for Research and Translational Research
Tetsuya Yamaguchi Executive Vice President
Head of Project & Lifecycle Management Unit
Supervisory responsibility for Project & Lifecycle Management (Marketing), Corporate Planning and Regulatory & Quality Management
In charge of Corporate Planning Dept.
Senior Vice President
Head of Project & Lifecycle Management Unit
In charge of Corporate Planning Dept.

Effective April 1, 2021

Director

NameNew ResponsibilitiesCurrent Responsibilities
Tatsuro Kosaka Representative Director, Chairman
Supervisory responsibility for Business Development and External Affairs
In charge of External Affairs Dept.
Representative Director, Chairman
Supervisory responsibility for Business Development and External Affairs

Executive Officers

NameNew ResponsibilitiesCurrent Responsibilities
Junichi Ebihara Senior Vice President
In charge of Legal Dept. and Intellectual Property Dept.
Senior Vice President
Head of Legal Dept.
In charge of Intellectual Property Dept.
Shinya Takuma Vice President
Head of Pharmaceutical Technology Div. and President of Chugai Pharma Manufacturing Co., Ltd.
Associate Vice President
Head of Pharmaceutical Technology Div. and President of Chugai Pharma Manufacturing Co., Ltd.
  • Keiji Kono is scheduled to retire from Senior Vice President as of March 31, 2021.
  • Hiroshi Murata and Masatoshi Takada are scheduled to retire from Vice Presidents as of March 31, 2021.

Please see the PDF file about other personnel changes.

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: 81-3-3273-0881
  • E-mail: [email protected]
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: 81-3-3273-0554
  • E-mail: [email protected]